AFQ056 Drug May Treat Fragile X

Introduction

The first drug to treat the underlying disorder instead of the symptoms of Fragile X, the most common cause of inherited intellectual disability, shows some promise, according to a new study published in the January issue of Science Translational Medicine. Rush University Medical Center researchers helped design the study and are now participating in the larger follow-up clinical trial.

Main Item

The data from the early trial of 30 Fragile X patients found the drug, called AFQ056, made by Novartis Pharmaceuticals, helped improve symptoms in some patients. Patients who had the best response have a kind of "fingerprint" in their DNA that could act as a marker to determine who should get treatment.

"This is an exciting development. It is the first time we have a treatment targeted to the underlying disorder, as opposed to supportive treatment of the behavioral symptoms, in a developmental brain disorder causing intellectual disability. This drug could be a model for treatment of other disorders such as autism," said pediatric neurologist Dr. Elizabeth Berry-Kravis, a study author and director of the Fragile X Clinic and Research Program and the Fragile X-Associated Disorders Program at Rush.

The drug is designed to block the activity of mGluR5, a receptor protein on brain cells involved in most aspects of normal brain function, including regulation of the strength of brain connections, a key process required for learning and memory. Fragile X patients have a mutation in a single gene, known as Fragile X Mental Retardation-1 or FMR1. The mutation prevents FMR1 from making its protein, FMRP, so FMRP is missing in the brain. FMRP normally acts as a blocker or "brake" for brain cell pathways activated by mGluR5. When FMRP is missing, mGluR5 pathways are over-active resulting in abnormal connections in the brain and the behavioral and cognitive impairments associated with Fragile X.

The research team, led by Sebastien Jacquemont of Vaudois University in Switzerland in collaboration with Baltazar Gomez-Mancilla of Novartis, found no significant effects of treatment when the entire group of 30 patients was analyzed. However, in a subsequent analysis, seven patients with a fully methylated gene, which was fully shut down, presumably resulting in no FMR protein in the blood or brain, showed significant improvement in behavior, hyperactivity, and inappropriate behavior speech with the treatment compared to placebo.

"The treatment period in this pilot study was concise, and longer treatment might have been needed to see improvement in the whole group of patients. Importantly, the drug was well-tolerated, and there were no safety problems," said Berry-Kravis.

A larger drug study will recruit 160 patients worldwide and test the effects of a longer treatment period. Rush University Medical Center is one of the participating sites.

Fragile X affects 1 in 4000 males and 1 in 6000 females of all races and ethnic groups. It is the most common single gene cause of autism or "autistic-like" behaviors. Symptoms can also include characteristic physical and behavioral features and speech and language development delays. The impairment can range from learning disabilities to more severe cognitive and intellectual disabilities.

Related Information

• Defining Fragile X Syndrome
• Could Fragile X Be Key to Autism Puzzle?
• Fragile X Syndrome: Genetic Clues Found
• Fragile X Study Provides Hope for Autism Treatment
• New Registry to Accelerate Research on Fragile X Syndrome
• Fragile X Syndrome Drug being Evaluated

Attribution/Source(s):
This peer reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its significant relevance to the disability community. Originally authored by Rush University Medical Center, and published on 2011/01/09 (Edit Update: 2024/02/06), the content may have been edited for style, clarity, or brevity. For further details or clarifications, Rush University Medical Center can be contacted at rush.edu. NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Information and Page References

Disabled World (DW) is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): Rush University Medical Center. (2011, January 9 - Last revised: 2024, February 6). AFQ056 Drug May Treat Fragile X. Disabled World (DW). Retrieved January 14, 2025 from www.disabled-world.com/medical/pharmaceutical/fragile-x-drug.php

Permalink: <a href="https://www.disabled-world.com/medical/pharmaceutical/fragile-x-drug.php">AFQ056 Drug May Treat Fragile X</a>: Fragile X affects 1 in 4000 males and 1 in 6000 females of all races and ethnic groups. It is the most common single gene cause of autism or autistic-like behaviors.

While we strive to provide accurate and up-to-date information, it's important to note that our content is for general informational purposes only. We always recommend consulting qualified healthcare professionals for personalized medical advice. Any 3rd party offering or advertising does not constitute an endorsement.